Structure Therapeutics Inc. Depreciation
Structure Therapeutics Inc. (GPCR) reported Depreciation of $1.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-06
- Structure Therapeutics Inc. depreciation for the quarter ending 2026-06-30 was $551.00K, a 89.35% increase year-over-year.
- Structure Therapeutics Inc. depreciation for the quarter ending 2026-03-31 was $576.00K, a 110.22% increase year-over-year.
- Structure Therapeutics Inc. depreciation for the quarter ending 2025-12-31 was $412.00K, a 50.92% increase year-over-year.
- Structure Therapeutics Inc. depreciation for the quarter ending 2025-09-30 was $356.00K, a 34.34% increase year-over-year.
- Structure Therapeutics Inc. depreciation for fiscal 2025 was $1.33M, a 34.38% increase from fiscal 2024.
- Structure Therapeutics Inc. depreciation for fiscal 2024 was $992.00K, a 236.27% increase from fiscal 2023.
- Structure Therapeutics Inc. depreciation for fiscal 2023 was $295.00K, a 6.50% increase from fiscal 2022.
- Structure Therapeutics Inc. depreciation for fiscal 2022 was $277.00K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $551.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.13M 10-Q · filed 2026-08-06 | $1.54M derived: sum of 3 quarters · filed 2026-08-06 | $1.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $576.00K 10-Q · filed 2026-05-07 | $988.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.34M derived: sum of 3 quarters · filed 2026-05-07 | $1.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $412.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $768.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.06M derived: sum of 3 quarters · filed 2026-08-06 | $1.33M 10-K · filed 2026-02-26 |
| 2025-09-30 | $356.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $647.00K derived: sum of 2 quarters · filed 2026-08-06 | $921.00K 10-Q · filed 2025-11-06 | $1.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $291.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $565.00K 10-Q · filed 2026-08-06 | $838.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $274.00K 10-Q · filed 2026-05-07 | $547.00K derived: sum of 2 quarters · filed 2026-05-07 | $812.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.04M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $273.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $538.00K derived: sum of 2 quarters · filed 2026-02-26 | $770.00K derived: sum of 3 quarters · filed 2026-02-26 | $992.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $265.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $497.00K derived: sum of 2 quarters · filed 2025-11-06 | $719.00K 10-Q · filed 2025-11-06 | $791.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $232.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $454.00K 10-Q · filed 2025-08-06 | $526.00K derived: sum of 3 quarters · filed 2026-02-26 | $605.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $222.00K 10-Q · filed 2025-05-08 | $294.00K derived: sum of 2 quarters · filed 2026-02-26 | $373.00K derived: sum of 3 quarters · filed 2026-02-26 | $447.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $151.00K derived: sum of 2 quarters · filed 2026-02-26 | $225.00K derived: sum of 3 quarters · filed 2026-02-26 | $295.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $153.00K derived: sum of 2 quarters · filed 2024-11-13 | $223.00K 10-Q · filed 2024-11-13 | $295.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $144.00K 10-Q · filed 2024-08-08 | $216.00K derived: sum of 3 quarters · filed 2024-08-08 | $292.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $70.00K 10-Q · filed 2024-05-09 | $142.00K derived: sum of 2 quarters · filed 2024-05-09 | $218.00K derived: sum of 3 quarters · filed 2024-05-09 | $277.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $148.00K derived: sum of 2 quarters · filed 2024-03-08 | $207.00K derived: sum of 3 quarters · filed 2024-03-08 | $277.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | $76.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-17 | $135.00K derived: sum of 2 quarters · filed 2023-11-17 | $205.00K 10-Q · filed 2023-11-17 | |
| 2022-06-30 | $59.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-11-17 | $129.00K 10-Q/A · filed 2023-11-17 | ||
| 2022-03-31 | $70.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |